|Bid||400.00 x 100|
|Day's Range||453.35 - 459.25|
|52 Week Range||325.35 - 464.40|
|PE Ratio (TTM)||55.10|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Regeneron, Gilead and Biogen will benefit the most among biotechs under Trump's proposed tax reform, a measure that would cut the corporate tax rate by 20%.
Total prescriptions of Pfizer's eczema drug Eucrisa have flattened out over recent weeks as Regeneron and Sanofi's Dupixent has picked up steam.